LLY
The comeback nobody wanted to make
Eli Lilly dropped fresh late-stage data showing its obesity drugs can help patients maintain weight loss after they step down from stronger doses of injectable incretin therapy. In the two trials, people switching from Wegovy to Foundayo kept nearly all of their prior weight loss on average over a year, while patients moving from Zepbound MTD to Foundayo or reducing Zepbound to 5 mg also held onto most of the weight they’d already lost.
Why investors care
This is the part of the obesity story that can get lost in the headline-grabbing scale numbers. Losing weight is great; keeping it off is the real business problem. If Lilly can show its drugs help patients stay on track after dose changes or switches, that supports stickier demand and gives the company another angle in the GLP-1 arms race.
The subtle shot across the bow
The company also said people who stayed on Zepbound MTD for another year maintained all of their weight loss on average. Translation: Lilly is trying to prove its portfolio can win whether patients stay on the heavy-duty dose, step down, or switch brands. That’s a nice way of saying the competition is brutal and everyone’s trying to own the long game.
Big picture
For Lilly, obesity isn’t just a blockbuster market — it’s a treadmill, and not the cute gym kind. Data like this helps keep the narrative pointed toward durability, which is exactly what investors want when the category is crowded and the stakes are measured in billions.